Stock Financial Ratios, Dividends, Split History

AEL / American Equity Investment Life Holding Co. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price35.10
Volume497,100.00
Market Cap ($M)3,202.01
Enterprise Value ($M)2,427.77
Book Value ($M)2,546.99
Book Value / Share28.27
Price / Book1.26
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 89,880,222
Common Stock Shares Outstanding 89,331,087
Weighted Average Number Of Shares Outstanding Basic 88,982,442
Weighted Average Number Of Diluted Shares Outstanding 90,311,008
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.00
Return on Equity (ROE)0.08
Balance Sheet (mrq) ($M)
Assets61,301.32
Liabilities58,754.33
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Supplementary Insurance Information Premium Revenue234,722,000.00
Revenues3,891,652,000.00
Net Income174.65
Earnings Per Share Diluted1.93
Earnings Per Share Basic1.96
Cash Flow Statement (mra) ($M)
Cash From Operations1,922.39
Cash from Investing-2,591.94
Cash from Financing-2,591.94
Identifiers and Descriptors
CUSIP025676206
Central Index Key (CIK)1039828
Related CUSIPS
025676906 025676956
Industry Groups
SIC 6311 - Life Insurance

Split History

Stock splits are used by American Equity Investment Life Holding Co. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

American Equity Investment Life Holding's (AEL) CEO, John Matovina on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
American Equity Investment Life Holding Company (NYSE:AEL) Q1 2018 Earnings Conference Call May 3, 2018 9:00 AM ET (8-0)

Insure Your Portfolio with 4 Stocks Set to Beat Q1 Earnings

2018-04-26 investorplace
First-quarter earnings season has already witnessed 130 elite S&P 500 index members having reported quarterly results so far. Let’s see, how the quarter pans out for the life and non-life or the property and casualty (P&C) insurance space. (49-0)

4 Solid Insurance Stock Picks: Can These Continue the Bull Run?

2018-04-06 investorplace
As the year 2018 set in, the insurance industry started to witness the wheel of fortune turning in its favor with the rising interest rates, improving economy, lower-than-expected catastrophe loss (as compared to 2017, which emerged as the costliest year in terms of cat loss) as well as a noteworthy tax reform effective Jan 1, 2018. (71-0)

CUSIP: 025676206